Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel
BOSTON, May 30, 2019 /PRNewswire/ — Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, a next-generation sequencing (NGS) panel, received conditional approval by the New York State Department of Health for clinical use by the Laboratory of Personalized Genomic Medicine at Columbia University Medical […]
Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia
SAN FRANCISCO, CA, Jan. 10, 2019 /PRNEWSWIRE/ – Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA and Shanghai, China, is forming a strategic partnership and joint venture with China Biotech Services Holdings, Ltd (CBSH; HKSE:08037). The agreement was signed on January 9th at the JP Morgan Healthcare Conference in San Francisco. […]
Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material
Helen Fernandes, PhD, Co-director of Genomic Oncology at Columbia University, presented a talk on October 31, 2018 during the Corporate Workshop Day at the 2018 Association for Molecular Pathology (AMP) Annual Meeting in San Antonio, Texas. Click below to watch Dr. Fernandes’ talk: Click here In her talk, titled “Single-vial amplification-based NGS with rapid turn-around […]
Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp™ Technology
NATICK MASSACHUSETTS, Dec. 11, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces that key patents covering its SLIMamp™ technology have been issued in its most important markets China and the United States. The State Intellectual Property Office (SIPO) of […]
Pillar Biosciences announces ISO 13485:2016 Certification
NATICK MASSACHUSETTS, Nov. 29, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces it has received ISO 13485:2016 certification for design, development, manufacture, and distribution of products for the clinical oncology laboratory within a comprehensive quality management system (QMS). The […]
Pillar Biosciences to Collaborate with Illumina on Next-Generation Sequencing Based In Vitro Diagnostics Development
Illumina and Pillar Biosciences, Inc. today announced an agreement to develop next-generation sequencing (NGS) based in vitro diagnostic (IVD) tests. Under the terms of the agreement, Pillar Biosciences will lead the development of a series of diagnostic tests that will be run on the Illumina MiSeq™Dx instrument. Pillar Biosciences has developed Stem Loop Inhibition Mediated […]
ORI Healthcare Fund Invests in Pillar Biosciences
HONG KONG, CHINA—(Marketwired – May 11, 2016) – ORI Healthcare Fund L.P. (ORI Fund) announces the completion of US$18 million investment into Pillar Biosciences Inc., a Boston-based start-up specialized in next generation sequencing (“NGS”)-based clinical oncology testing in order to bring affordable precision medicine to cancer patients globally. Pillar Biosciences is prized with its patent-pending […]